StreetInsider.com News Articles

Form 8-K Glucotrack, Inc. For: Oct 28

Thu, 29 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261029/27259097.html

Form 8-K Glucotrack, Inc. For: Oct 23

Wed, 28 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261028/27249154.html

Form 8-K Glucotrack, Inc. For: Oct 22

Thu, 22 Oct 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20261022/27223585.html

Glucotrack announces 1-for-2 reverse stock split effective Oct. 26

Thu, 22 Oct 2026 09:00:54 -0400

Glucotrack, Inc. (Nasdaq: GCTK) announced a 1-for-2 reverse stock split of its issued and outstanding common stock, effective at the opening of trading on October 26, 2026.

The split will reduce the total number of outstanding shares from 2,368,237 to approximately 1,184,119. Every two shares of common stock will be combined into one share. Stockholder ownership percentages will remain unchanged, except for adjustments related to fractional shares. No fractional shares will be issued; instead, stockholders holding an odd number of shares will receive an additional fraction to round up to the next whole share.

Glucotrack's common stock will continue to trade on

Glucotrack, Inc. Announces Reverse Stock Split

Thu, 22 Oct 2026 09:00:00 -0400

1-for-2 reverse stock split to become effective as of the opening of trading on October 26, 2026

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)-- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a healthcare technology and biopharmaceutical company operating Lōkahi Therapeutics™, today announced that it will effect a 1-for-2 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock, par value $0.001 per share (the “Common Stock”), effective with the opening of trading on Monday, October 26, 2026.

Glucotrack’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol

Glucotrack, Inc. Announces Reverse Stock Split

Thu, 22 Oct 2026 09:00:00 -0400

1-for-2 reverse stock split to become effective as of the opening of trading on October 26, 2026

Glucotrack’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol

Form 8-K Glucotrack, Inc. For: Oct 13

Mon, 19 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261019/27203879.html

Form PRE 14A Glucotrack, Inc. For: Oct 13

Wed, 14 Oct 2026 10:02:00 -0400

si-local-file:///var/storage/secattach/20261014/27185400.html

Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications

Wed, 14 Oct 2026 09:00:00 -0400

Now free on the App Store and Google Play, Qare matches users into cohorts by medication and demographic profile, generating a database of user-reported real-world experience data that Lōkahi believes may become a source of long-term value to patients and manufacturers

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)-- Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced the public launch of Qare™, a comparative health platform designed to help users compare self-reported treatment experiences across medications within the same therapeutic class. Launching initially in the GLP-1 category, Qare™ enables users to compare their self-reported results,

Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications

Wed, 14 Oct 2026 09:00:00 -0400

Form S-1/A Glucotrack, Inc.

Wed, 14 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261014/27183173.html

Form 425 Glucotrack, Inc. Filed by: Glucotrack, Inc.

Tue, 13 Oct 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20261013/27181693.html

Form 8-K/A Glucotrack, Inc. For: Jul 09

Tue, 13 Oct 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20261013/27181683.html

Lōkahi Therapeutics™ Expands University of Georgia Collaboration Through First International ai² Pipeline™ Project with Universität Paderborn

Thu, 01 Oct 2026 17:15:00 -0400

Cross-border initiative expands Lōkahi's university network, increases capacity for additional revenue generating strategic partnerships, and brings together U.S. and German students to identify and evaluate international therapeutic assets with potential for U.S. development and commercialization

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)-- Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced a new international project with the University of Georgia's Student Industry Fellows Program and Universität Paderborn's garage33 entrepreneurship and innovation center. The Fall 2026 initiative represents the first international expansion of Lōkahi's university-enabled asset evaluation model and builds on its successful collaboration with the University

Lōkahi Therapeutics™ Expands University of Georgia Collaboration Through First International ai² Pipeline™ Project with Universität Paderborn

Thu, 01 Oct 2026 17:15:00 -0400

Glucotrack unit to launch GLP-1 patient comparison app in October

Wed, 30 Sep 2026 09:01:27 -0400

Lōkahi Therapeutics, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), announced a platform called Qare, designed to allow patients using GLP-1 medications to compare their treatment experiences against those of other users. The company said the platform is expected to become publicly available on October 14, 2026.

Qare is described as a comparative health platform that lets users document, organize, and analyze their treatment experiences relative to patient cohorts using different medications within the same therapeutic class. The company said additional drug categories are expected to be added in future releases.

The platform was developed through Lōkahi's ai² Accelerator program and was introduced

Lōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14

Wed, 30 Sep 2026 09:00:00 -0400

Developed Through ai² Accelerator™, Qare™ Is Designed to Enable Users to Compare Their Experiences Against Cohorts of People Like Them, with Additional Drug Classes Expected to Follow

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)-- Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced Qare™, a comparative health platform designed to evaluate treatment outcomes by comparing experiences across patients using different medications within the same therapeutic class. Introduced on National GLP-1 Day, Qare™ is expected to become publicly available on October 14, 2026.

Launching initially in the GLP-1 category, Qare™ is designed to provide a platform for GLP-1

Lōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14

Wed, 30 Sep 2026 09:00:00 -0400

Developed Through ai² Accelerator™, Qare™ Is Designed to Enable Users to Compare Their Experiences Against Cohorts of People Like Them, with Additional Drug Classes Expected to Follow

Launching initially in the GLP-1 category, Qare™ is designed to provide a platform for GLP-1

Form 8-K Glucotrack, Inc. For: Sep 22

Mon, 28 Sep 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260928/27115647.html

Form 424B5 Glucotrack, Inc.

Mon, 28 Sep 2026 11:50:00 -0400

si-local-file:///var/storage/secattach/20260928/27112153.html

Lōkahi Therapeutics partners with Pepperdine on pipeline program

Fri, 25 Sep 2026 09:00:34 -0400

Lōkahi Therapeutics, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), has announced a collaboration with Pepperdine E2B (Education to Business) to involve MBA students in its ai2 Pipeline program during the upcoming academic year.

The collaboration will begin with a project involving full-time MBA students enrolled in a marketing course at the Pepperdine Graziadio Business School, taught by Professor Kimber Maderazzo. Students will work alongside Lōkahi professionals to identify, evaluate, and prioritize therapeutic opportunities, assessing scientific, regulatory, intellectual property, commercial, and strategic factors relevant to biopharmaceutical asset development.

According to the company, the ai2 Futures Lab program engaged 64 students in its first

Lōkahi Therapeutics™ Expands ai² Pipeline™ Program Through Collaboration with Pepperdine E2B™

Fri, 25 Sep 2026 09:00:00 -0400

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)-- Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced that it will partner with Pepperdine E2B™ (Education to Business) to engage students in its ai2 Pipeline™ initiative during the upcoming academic year. The collaboration is intended to provide students with hands-on experience evaluating real-world biopharmaceutical opportunities while supporting Lōkahi's ongoing efforts to identify and assess therapeutic assets through its ai2 platform.

The Pepperdine collaboration will begin with a project involving full-time MBA students in a marketing course taught by Professor Kimber Maderazzo at the Pepperdine Graziadio Business School. Through

Lōkahi Therapeutics™ Expands ai² Pipeline™ Program Through Collaboration with Pepperdine E2B™

Fri, 25 Sep 2026 09:00:00 -0400

The Pepperdine collaboration will begin with a project involving full-time MBA students in a marketing course taught by Professor Kimber Maderazzo at the Pepperdine Graziadio Business School. Through

Form 424B5 Glucotrack, Inc.

Thu, 24 Sep 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260924/27102972.html

Form 8-K Glucotrack, Inc. For: Sep 24

Thu, 24 Sep 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260924/27102920.html